Psoriasis: Ustekinumab and Other Biologics in the Pipeline

Noori Kim, Alice B. Gottlieb

Research output: Contribution to journalReview articlepeer-review

Abstract

The improved understanding of the complex immunology and pathogenesis of psoriasis and psoriatic arthritis has established the therapeutic utility of targeted biologic therapies against the pathogenic T cells and the inflammatory cytokines. Particular interest in the interleukin (IL)-23/T helper (Th)17 pathway has led to the development of ustekinumab, which is now approved and widely marketed for the treatment of psoriasis, as well as various investigational biologic agents in current clinical trials. Lack of or improper treatment of psoriasis and psoriatic arthritis can inevitably result in considerable morbidity and quality of life issues for affected patients, emphasizing the continued need for drug research and development to achieve optimal management.

Original languageEnglish (US)
Pages (from-to)108-114
Number of pages7
JournalCurrent Dermatology Reports
Volume1
Issue number3
DOIs
StatePublished - Sep 2012
Externally publishedYes

Keywords

  • Biologics
  • Briakinumab
  • Comorbidities
  • Cytokines
  • Dermatopharmacology
  • IL-12
  • IL-17
  • IL-22
  • IL-23
  • IL-23 inhibitors
  • IL-23/Th17 pathway
  • Immunology
  • Pathogenesis
  • Psoriasis
  • Psoriatic arthritis
  • T cells
  • T-cell modulators
  • TNF inhibitors
  • TNF-α
  • Therapy
  • Tumor necrosis factor-alpha
  • Ustekinumab

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Psoriasis: Ustekinumab and Other Biologics in the Pipeline'. Together they form a unique fingerprint.

Cite this